PROF · Profound Medical Corp.

Track PROF — free

$5.97 +0.01 (+0.17%) At close · Sep 11

Rebalance outlook locked

Market Cap

$218.10M

36.53M

Up next

Next earnings call

Oct 22, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

4.0

Trailing earnings · reciprocal yield 25.2%

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+21.0%

Year over year · more shares

Price change (1Y)

+54.0%

Trailing year

Short interest

4.4%

Latest settlement · 14.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −14%

below

Price vs 50-day avg −15%

below

RSI (14) 30

neutral

MACD trend Negative

52-week position 43%

mid-range

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Weak

1-month return −10%

trailing

6-month return +18%

trailing

YTD return −24%

this year

Relative strength 0%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $7 › 200d $7 — 50d above 200d

Institutional flow Distributing

-2% holders QoQ · +5 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

4.43% of float · ▼ -12.0% MoM · 14.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

57 holders — mid 3-yr range

Squeeze score 53

elevated · 0–100

Fundamentals

Excellent

Revenue growth +51%

Y/Y

Gross margin 71%

expanding

EPS growth +26%

Y/Y

Free cash flow $-38.4M

Balance sheet $55.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 70%

annualized · 1-yr

Max drawdown −42%

past year

ATR 7.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 6, 2026

Total revenue · full-year 2026 Initiated $25M

prior FY $16.1M midpoint +55.3% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−14% Bearish

Price vs 50-day avg

−15% Bearish

RSI (14)

30 Neutral

MACD trend

Negative Bearish

52-week position

43% Neutral

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $7 › 200d $7 — 50d above 200d

Institutional flow Distributing

-2% holders QoQ · +5 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

4.43% of float · ▼ -12.0% MoM · 14.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

57 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $4 Now $6 · 43% Range high $9

vs 200-day avg -14% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PROF Profound Medical Corp. this stock	$218.10M	-24.1%	+50.7%	—	4.4%
ABT Abbott Laboratories	$178.08B	-18.6%	+5.7%	28.6	1.3%
MDT Medtronic plc	$116.35B	-5.3%	+8.4%	22.4	0.9%
SYK Stryker Corp	$103.43B	-21.6%	+11.2%	27.9	2.0%
BSX Boston Scientific Corp	$62.29B	-54.9%	+12.5%	17.4	3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

% held: 44.3%
Net QoQ: -254.7K sh
Top holder: FIL Ltd

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

1.6M

Days to cover: 14.5d
Change: -221.1K sh

View

Short Volume

Short vol %

70%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

4.6K

Value: $31.8K
As of: Aug 12, 2026

View

Off-Exchange

Off-exchange %

44.1%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Tom Malinowski

Amount: $1.0K–$15.0K
Traded: Jul 21, 2020

View

Financials

Revenue (FY)

$16.1M

Net income (FY): $-42.6M
EPS diluted: $1.41

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 4, 2026
This year: 30

View

Proposed Sales

Value

$105.5K

Shares: 13.0K
Filed: Nov 12, 2024

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
PROF	-12.2%	-10.5%	+18.0%	-12.2%	-24.1%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-11.1%	-8.7%	+0.1%	-11.9%	-36.2%

Key facts CIK 1628808 CUSIP 74319B502 13F (30d) 29 filings 29 filers Visit website Investor relations

PROF · Profound Medical Corp.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance